MDT

Medtronic
D

MDT

Arincen70/100B

Medtronic free cash flow 1990–2027

Medtronic's free cash flow in Q1 FY2027, the three months to 31 July 2026, was 1.29B USD, up 120.9% on the same quarter a year before. Medtronic's free cash flow over the last twelve months was 6.13B USD, up 15.6% on the twelve months before. In fiscal year 2026 it was 5.43B USD, up 4.6% on the year before.

Last updated 6 Nov 2026 · Next report 24 Nov 2026

Free cash flow

Free cash flow · +2.7% a year over 10 yearsFree cash flow margin

Growth

Fiscal yearPeriod endingFree cash flowGrowthFree cash flow marginOperating cash flowCapital expenditureFree cash flow per share
TTM31 Jul 20266.13B+15.63%16.33%8.04B-1.90B4.76
FY202624 Apr 20265.43B+4.65%14.92%7.33B-1.90B4.21
FY202525 Apr 20255.19B-0.29%15.46%7.04B-1.86B4.02
FY202426 Apr 20245.20B+13.54%16.07%6.79B-1.59B3.91
FY202328 Apr 20234.58B-23.39%14.67%6.04B-1.46B3.44
FY202229 Apr 20225.98B+22.37%18.87%7.35B-1.37B4.42
FY202130 Apr 20214.89B-18.87%16.22%6.24B-1.36B3.61
FY202030 Apr 20206.02B+2.52%20.82%7.23B-1.21B4.46
FY201926 Apr 20195.87B+62.42%19.22%7.01B-1.13B4.33
FY201827 Apr 20183.62B-35.73%12.07%4.68B-1.07B2.64
FY201728 Apr 20175.63B+34.85%18.94%6.88B-1.25B4.04
FY201629 Apr 20164.17B-3.67%14.47%5.22B-1.05B2.93
FY201530 Apr 20154.33B-5.08%21.38%4.90B-571.00M3.91
FY201425 Apr 20144.56B+3.10%26.83%4.96B-396.00M4.50
FY201330 Apr 20134.43B+12.28%26.68%4.88B-457.00M4.31
FY201230 Apr 20123.94B+23.46%24.36%4.47B-528.00M3.72
FY201130 Apr 20113.19B-8.67%20.04%3.74B-548.00M2.95
FY201030 Apr 20103.50B+8.74%22.10%4.13B-635.00M3.15
FY200930 Apr 20093.22B+11.52%22.02%3.88B-663.00M2.85
FY200830 Apr 20082.88B+26.17%21.33%3.49B-606.00M2.52
FY200730 Apr 20072.29B+137.23%18.58%2.98B-694.00M1.97
FY200630 Apr 2006963.20M-59.31%8.53%2.21B-1.24B0.79
FY200530 Apr 20052.37B-2.22%23.55%2.82B-452.00M1.94
FY200430 Apr 20042.42B+42.61%26.64%2.85B-424.60M1.98
FY200330 Apr 20031.70B+41.04%22.15%2.08B-380.40M1.38
FY200230 Apr 20021.20B-13.51%18.78%1.59B-386.40M0.98
FY200130 Apr 20011.39B+98.86%25.07%1.83B-439.70M1.14
FY200030 Apr 2000699.90M—13.96%1.04B-342.10M0.57
FY199930 Apr 1999-788.50M-244.71%-19.07%455.30M-1.24B-0.65
FY199830 Apr 1998544.90M+99.31%20.92%693.10M-148.20M0.46
FY199730 Apr 1997273.40M-18.80%11.21%463.60M-190.20M0.23
FY199630 Apr 1996336.70M+15.98%15.52%500.50M-163.80M0.35
FY199530 Apr 1995290.30M-1.96%16.66%387.20M-96.90M0.31
FY199430 Apr 1994296.10M+38.11%21.29%356.90M-60.80M0.32
FY199330 Apr 1993214.40M+188.95%16.14%291.50M-77.10M0.23
FY199230 Apr 199274.20M+22.04%6.30%151.40M-77.20M0.08
FY199130 Apr 199160.80M+18.06%5.95%126.60M-65.80M0.06
FY199030 Apr 199051.50M—6.16%106.80M-55.30M0.06

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Stock buybacks,Cash flow

Common questions about Medtronic's free cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.